Lubiprostone News and Research

RSS
RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Researchers find better way to prep patients for colonoscopy procedures

Researchers find better way to prep patients for colonoscopy procedures

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Swissmedic grants marketing authorization for Amitiza

Swissmedic grants marketing authorization for Amitiza

European MAA for lubiprostone withdrawn by Sucampo Pharma Europe

European MAA for lubiprostone withdrawn by Sucampo Pharma Europe

Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan

Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan

Updated guidelines for irritable bowel syndrome

Updated guidelines for irritable bowel syndrome

Lubiprostone brings relief for many IBS patients who experience constipation

Lubiprostone brings relief for many IBS patients who experience constipation

FDA approves Amitiza for irritable bowel syndrome with constipation

FDA approves Amitiza for irritable bowel syndrome with constipation

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome with constipation

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome with constipation

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome

Cognitive behavioral therapy effective in treating irritable bowel syndrome

Cognitive behavioral therapy effective in treating irritable bowel syndrome